Giving mice a modified version of a naturally occurring gene blocks cocaine’s stimulant effects without affecting the animals’ physiological or metabolic health. The new evidence advances the proposed therapy a step closer to readiness for testing in people.
In the first long-term follow-up of patients treated with buprenorphine/naloxone for addiction to opioid pain relievers, half reported that they were abstinent from the drugs 18 months after starting the therapy.
Young adults who had been maltreated as children differed from others who had not been maltreated in the connectivity of nine cortical regions. The differences could compromise the maltreated group’s basic social perceptual skills, ability to maintain a healthy balance between introversion and extroversion, and ability to self-regulate their emotions and behavior.
Two researchers share their reasons for researching transcranial magnetic stimulation (TMS) for treating cocaine addiction, and describe challenges to moving forward this potentially promising therapy.